Skip to content
Medical Health Aged Care

Dementia Australia supports Warrnambool

Dementia Australia 2 mins read

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Warrnambool on Tuesday 3 June 2025.

There is estimated 772 people living with dementia in Warrnambool. Without a medical breakthrough this number is expected to increase to approximately 1,488 people by 2054.

Dementia Australia is hosting a free afternoon information session at City Memorial Bowls Club for anyone who wants to learn more about dementia.

Warrnambool residents impacted by dementia and those who want to learn more are encouraged to attend. Please note this session is not suitable for professionals employed in the health or aged care sectors.

Bookings are essential. Please register online or contact the National Dementia Helpline on 1800 100 500 or dementia.org.au/helpline for more information. The National Dementia Helpline is available 24 hours, seven days a week.

 

-Ends-

 

Dementia Australia is the source of trusted information, education and services for the estimated 433,300 Australians living with dementia, and the estimated 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Andrea Hogan, Media and Communications Manager, 0406 904 118, [email protected]
                              

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors: We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 12/04/2026
  • 07:10
Energy Enhancement System

Court Rules Against Jason Shurka in EESystem Case; $54,034 in Federal Sanctions Ordered

Clark County judge finds defendant’s public statements were not made in good faith. The ruling caps months of legal proceedings brought by the inventor…

  • Contains:
  • Medical Health Aged Care
  • 12/04/2026
  • 06:25
Royal Australian College of GPs

Cleanbill report shows bulk billing rises where funding is strongest, not where competition is greatest

The Royal Australian College of General Practitioners (RACGP) says new Cleanbill data indicates what GPs have consistently warned is true: bulk billing increases where funding better reflects the true cost of care, not where there is greater competition between practices. The Cleanbill report, released today, breaks down bulk billing and gap fees by how rural a practice is based on Modified Monash Model (MM1–7) classification. It shows that the largest increases in 100% bulk billing have occurred in regional and rural areas where government incentives are highest, yet where health department data show there are fewer GPs per person. RACGP…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 10/04/2026
  • 11:12
Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifyingimmunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical industry and, specifically, the allergy therapeutics field. Andrew has deep pharmaceutical industry expertise spanning development, product launch, fundraising and exits from working with large and small companies in the U.S. and Europe. As Chief Commercial Officer he built the global commercial organisation for the approval and launch in the US…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.